#1G A G A G A G A T Ĉ A T G A T G G A G G G A T A A A T T G G G A G X²² 23andMe Investor Presentation August 2022 A A C G G G A C C C G G C C C C G A T G A G A G G C C T A T T C A A G G A G C#2Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe's businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated in this presentation, including statements regarding 23and Me's strategy, financial position, funding for continued operations, cash reserves, projected costs, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "continue," "will," "schedule," and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe's current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe's forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Except as required by law, 23andMe does not undertake any obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise. Use of Non-GAAP Financial Measures To supplement the 23andMe's unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America ("GAAP"), this presentation also includes references to Adjusted EBITDA, which is a non-GAAP financial measure that 23andMe defines as net income before net interest expense (income), net other expense (income), changes in fair value of warrant liabilities, income tax (provision) benefit, depreciation and amortization of fixed assets, amortization of internal use software, amortization of acquired intangible assets, non-cash stock-based compensation expense, acquisition-related costs, litigation settlements not related to normal and continued business activities and expenses related to restructuring and other charges, if applicable for the period. 23andMe has provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this presentation. Adjusted EBITDA is a key measure used by 23andMe's management and the board of directors to understand and evaluate operating performance and trends, to prepare and approve 23andMe's annual budget and to develop short- and long-term operating plans. 23andMe provides Adjusted EBITDA because 23andMe believes it is frequently used by analysts, investors and other interested parties to evaluate companies in its industry and it facilitates comparisons on a consistent basis across reporting periods. Further, 23andMe believes it is helpful in highlighting trends in its operating results because it excludes items that are not indicative of 23andMe's core operating performance. In particular, 23andMe believes that the exclusion of the items eliminated in calculating Adjusted EBITDA provides useful measures for period-to-period comparisons of 23andMe's business. Accordingly, 23andMe believes that Adjusted EBITDA provides useful information in understanding and evaluating operating results in the same manner as 23and Me's management and board of directors. In evaluating Adjusted EBITDA, you should be aware that in the future 23andMe will incur expenses similar to the adjustments in this presentation. 23andMe's presentation of Adjusted EBITDA should not be construed as an inference that future results will be unaffected by these expenses or any unusual or non-recurring items. Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. Other companies, including companies in the same industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA as a tool for comparison. There are a number of limitations related to the use of these non-GAAP financial measures rather than net loss, which is the most directly comparable financial measure calculated in accordance with GAAP. Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. When evaluating 23andMe's performance, you should consider Adjusted EBITDA alongside other financial performance measures, including net loss and other GAAP results. Intellectual Property All rights to the trademarks, copyrights, logos and other intellectual property listed herein belong to their respective owners 23andMe's use thereof does not imply an affiliation with, or endorsement by the owners of such trademarks, copyrights, logos and other intellectual property. Solely for convenience, trademarks and trade names referred to in this Presentation may appear with the or TM symbols, but such references are not intended to indicate, in any way, that such names and logos are trademarks or registered trademarks of 23andMe. Industry and Market Data This Presentation relies on and refers to certain information and statistics based on 23andMe's management's estimates, and/or obtained from third party sources which it believes to be reliable. 23andMe has not independently verified the accuracy or completeness of any such third party information. Copyright © 2022 23and Me, Inc. 23andMe 2#3C Behind Every Data Point Is A Human Being G C T#4Our Mission is to Help People Access, Understand, and Benefit from the Human Genome 1 As of June 30, 2022. 23andMe Welcome to you saliva collection kit 23andMe REGENERON MILLION VETERAN PROGRAM UK BIOBANK DECODE GENETICS ALL OF US FINNGEN GENOMICS ENGLAND 825,000 1.65M 500,000 500,000 366,000 219,000 100,000 Size and scale of 23andMe enables rapid, novel discoveries Copyright © 2022 23and Me, Inc. 23andMe 13.1M¹ 4#5The Healthcare System is Dysfunctional "Of course our system isn't about healthcare, it's about maximizing revenue for a whole bunch of different players that have nothing to do with what's good for patients." Elisabeth Rosenthal (Editor-in-Chief, Kaiser Health News) 1 JAMA, "Waste in the US Health Care System" (2019). 2 Redpoint Global / Dynata survey of over 1,000 U.S. consumers (2020). 3 Gallup, "Americans' Views of U.S. Business and Industry Sectors" (2020). 4 PhRMA, "Biopharmaceutical Research & Development: The Process Behind New Medicines" (2015). 25% U.S. healthcare spending is waste 1 2 75% Consumers wish their healthcare experience was more personalized -15¹ The net positive score Americans gave the pharmaceutical industry Copyright © 2022 23and Me, Inc. <12%* Probability of success for a drug to be approved, taking ~10 years and costing $2.6B to develop 23and Me 5#6Media Commerce Hospitality >>> Healthcare Transportation >>> Uber >>> amazon ► YouTube >>> >> airbnb X 23andMe Consumer Scale and Empowerment is the Key to Disrupting Healthcare "Healthcare cannot change from within, it will need an outside force to change it, and that force will be our customers." Anne Wojcicki#7We Pioneered Digital DTC Healthcare to Empower Customers With Affordable, Direct Access ¹ See FDA De Novo Authorizations 140044, 160026, 170046 and 180028 and FDA 510K Clearances K182784 and K193492. 7 FDA Authorizations. TIME MAGAZINE INVENTION OF THE YEAR 1. The Retail DNA Test By Anita Hamilton Wednesday, Oct. 29, 2008 Best Inventions of 2008 > From a genetic testing service to an invisibility doak to an ingenious public bike system to the world's first moving skyscraper-here are TIME's picks for the top innovations of 2008 Proven accuracy (99% NPV/PPV) and accessibility¹ 2015 2016 2017 2019 2020 Carrier Status (inherited conditions) 2018 PGt (pharmacogenetic metabolism) 2021 GHR (genetic health risk) BRCA (breast and ovarian cancer) MUTYH (colorectal cancer) PGt (pharmacogenetic drug response) HOXB13 (prostate cancer)#880% Customers receive a report with a meaningful genetic variant 18,000+ Customers with an increased risk for Chronic Kidney Disease 8,000+ 12,000+ Customers with a tested BRCA1 / BRCA2 variant Customers with Hypercholesterolemia (FH) variants Note: Estimates based on prevalence of variants in 23andMe's Database as of June 30, 2022. Providing Customers With Key, Actionable Insights "Like me, there are many women who have slipped through the cracks of our current medical screening system, either because they don't have a family history of breast or ovarian cancer. Or they do not know that they have Ashkenazi Jewish ancestry. In my case, even though I know I have Ashkenazi ancestry, that wasn't enough to prompt my doctor to consider screening. So there are many women walking around with this risk, who, like me, would have never known of their own risk but for this test from 23andMe." 23andMe customer who discovered she had a BRCA1 mutation#9Transforming Healthcare With 23andMe's Crowdsourced, Genetic Database G 2 C "The mission of 23andMe is not just about genetics. We want to transform healthcare... What I have learned after 11 years is that people want to participate in research...They don't want to be a human subject. They want to be respected as an equal and as a partner in the process." с G Anne Wojcicki to Recode Decode (2018) C с C#10G Unlocking the Genetic Code Creates the Opportunity to Revolutionize the Diagnosis, Prevention and Treatment of Most, if Not All, Human Disease T T G Cracking the code... ACGT ...is a data problem, a very big data problem We are all 99.5% genetically alike 3 billion base pairs long Copyright © 2022 23and Me, Inc. 23andMe 10#11We Are Redefining Healthcare. With Data. At Scale. Cumulative Genotyped Customers (in M, fiscal year ends March 31) 2.0 FY17A 4.4 FY18A 7.8 FY19A 10M+ Genetic Profiles Created Critical Mass 9.8 FY20A 11.3 FY21A 1. As of June 30, 2022. 2. As of March 31, 2022. Programs include collaborated, 100% owned and royalty interest targets. 12.8 FY22A 13.1 FY23Q1 Empowering Consumers 13.1M Genotyped Customers¹ Enabling Research & Services 425K 23andMe+ Subscribers² 4B+ Phenotypic Data Points² Developing Therapeutics 50+ Programs² Copyright © 2022 23and Me, Inc. 23andMe 11#12Consumer Powered Healthcare Flywheel We run hundreds of billions of association tests per year that further our unique understanding of human biology Consumer 13.1M Genotyped Customers¹ KK Data 80% Opt-In to Research Research lolli Phenotypic Data XX 1. As of June 30, 2022. 2. As of March 31, 2022. Programs include collaborated, 100% owned and royalty interest targets. Genetic Data Insights 4B+ Phenotypic Data Points² Innovative Results Return value to the Customer Therapeutics / Product Drug Discoveries 50+ Programs² Copyright © 2022 23and Me, Inc. Novel Consumer Products >>> 23andMe 12#13Ancestry Composition Ancestry Composition East Asian & Native American 51.2% Chinese & Southeast Asian Chinese Vietnamese Indonesian, Thai, Khmer & Sub-Saharan African West African Nigerian Ghanaian, Liberian & Sierra Leonean 47.9% 42.9% 30% 35.2% 26.5% 14.396 4.M Our Ancestry Service A Mass Entry Point to Building a Revolutionary Database Note: Opt-in required for DNA Relatives and Family Tree builder. DNA Relatives DNA Relatives SORT: PERCENT JC LC SC NB VIEW MAP Jocelyn C Mother 50% DNA Shared Leo Cavani Father 50% DNA Shared Sam Cavani 1st Cousin 9.66% DNA Shared Nick Bolton 2nd Cousin 3,69% DNA Shared Visualize Genetic Connections With an Automatically Built Family Tree Your Family Tree ? ? ? Barbara Miller The Coun HOME Sandra Miller 6--0 Christopher Monis ANCESTRY ? CK Cory King Jamie King HEALTH PK Phillip King Cecille King Copyright © 2022 23and Me, Inc. RESEARCH ? Sam Garfield 11 Rachel Garfield ? FAMILY & FRIENDS Gertrude King 23and Me Linie Frank Susan Martin 13#14How Ancestry Matters In Connection To Your Health Current clinical guidelines and eligibility for insurance coverage limit BRCA testing to women with a personal or family history of cancer (Robson, 2003) Ann M. 23andMe Customer Ann did not know her ancestry origins and would not have been eligible for clinical testing under current guidelines. Ann decided to do 23andMe to learn more about her potential health risks. Based on her 23andMe report, she discovered she had a BRCA1 mutation. Her doctor confirmed the results and she opted to have surgeries to reduce her risk of having ovarian and/or breast cancer. ¹ NCCN is the National Comprehensive Cancer Network® (NCCNⓇ). 20% Adult individuals with a BRCA1 or BRCA2 variant Meet NCCNⓇ criteria¹ Identified by healthcare system 50% 80% Missed by healthcare system KKK DTC Testing Do not meet NCCN® criteria 45% 21% 50% KK No first-degree family history of a BRCA-related cancer Did not self-report having Jewish ancestry Copyright © 2022 23and Me, Inc. 23andMe 14#15Health Predispositions¹ 30+ Including: Type 2 Diabetes (Powered by 23andMe Research) Coronary Artery Disease 23 andMe+ Uterine Fibroids 23andMe+ Migraine 23andMe+ MUTYH-Associated Polyposis BRCA1/BRCA2 (selected variants) Type 2 Diabetes YOUR RESULT Our Health Service The First and Only Multi-Disease DTC Personal Genome Service (PGS) That Includes FDA-Authorized Reports and Provides Personalized Genetic Insights and Tools Your genetics are associated with a typical likelihood. XX 37% Wellness² 10 Including: Muscle Composition Genetic Weight Alcohol Flush Reaction Saturated Fat and Weight Sleep Movement Dog & Cat Allergies 23andMe+ Genetic Weight YOUR FEE Your genes predispose you to weigh about 7% less than average. Avign 142 Carrier Status 40+ Including: Cystic Fibrosis Sickle Cell Anemia Familial Hyperinsulinism (ABCC8-Related) Tay-Sachs Disease Glycogen Storage Disease (Type 1a) Chrome Tay-Sachs Disease YOUR RESULT You do not have the variants we tested. 0 variants detected 1. Includes FDA Authorized Genetic Health Risk Reports and Wellness Reports for Genetic Likelihood Powered by 23and Me Research. 2. Wellness information does not require FDA Authorization. Pharmacogenetics 3 Including: SLC01B1 Drug Transport CYP2C19 Drug Metabolism DPYD Drug Metabolism e.g., citalopram and clopidogrel Copyright © 2022 23and Me, Inc. Pharmacogenetics Genetic variants may influence how you process medications. YOUR PESULTS CYP2C19 Drug Metabolism LIKELY NORMAL METABOLIZER DPYD Drug Metabolism LIKELY NORMAL METABOLIZER SLC01B1 Drug Transport LIKELY NORMAL FUNCTION Print summary 7 FDA Authorizations > 23andMe+ 23andMe 15#16A Meaningful, Engaging (and Fun) Experience Strong Engagement and Trust Drive Longitudinal Data Collection ~80% customers consent to research 4B+ phenotypic data points 180+ published research papers Ice Cream Flavor Preference YOUR RESULT You are more likely to prefer chocolate ice cream. 56% of people with results like yours prefer chocolate ice cream. Neanderthal Ancestry Hey Jaime, You have more Neanderthal DNA than 78% of other customers. Neanderthals were prehistoric humans who interbred with modern humans before disappearing around 40,000 years ago. 16#1723andMe+ Subscription service that offers additional insights and features to give members even more actionable information to live healthier lives Pharmacogenetics 3 reports (FDA-Authorized) Heart Health Reports Atrial Fibrillation, Coronary Artery Disease, LDL Cholesterol, Hypertension DNA Relatives Advanced filters, access up to 5,000 relatives Polygenic Risk Scores (Powered by 23andMe Research) Rapidly discovering new genetic insights: Cancer risk Reproductive Health Diet Sleep Fitness and injuries Migraines Heart Health Learn how your DNA insights can help you care for your heart. LA 23andMe + Atrial Fibrillation INCREASED LIKELIHOOD Type 2 Diabetes INCREASED LIKELIHOOD 23andMe + Coronary Artery Disease TYPICAL LIKELIHOOD 23andMe + High Blood Pressure TYPICAL LIKELIHOOD 23andMe + LDL Cholesterol TYPICAL LIKELIHOOD#18Transforming Healthcare with Genetic Health Services at Scale C 3 G C T#19Today's Healthcare System Has Only a Small Impact on Our Health and Well Being 1. Schroeder, SA. (2007). We Can Do Better - Improving the Health of the American People. NEJM. 357:1221-8. Impact of Different Factors on Risk of Premature Death1¹ Social & Environmental Factors 20% Individual Behavior 40% Health and Well-being Health Care 10% Genetics 30%#20Genetic Data Helps Drive Behavior Change ¹ Based on 2019 online survey, designed by 23andMe and M/A/R/C Research, of 1,046 23andMe Health + Ancestry customers. 76% Report taking a positive health action¹ Eat healthier Set future goals to be healthier Adopt a healthier lifestyle in general Exercise more Get more rest / sleep Stop drinking / drink less Stop smoking / smoke less 7% 16% Copyright © 2022 23and Me, Inc. 45% 42% 23andMe 51% 50% 55% 20#21Opportunity for Personalized Healthcare at Scale Practice of Medicine Today Reactive - no customization until symptomatic ¶¶¶¶¶ P 23andMe+ Proactive - truly individualized from the very beginning >> >>> >>> >>> Copyright © 2022 23and Me, Inc. 23andMe 21#22Opportunity to Deliver Genetic Health Services at Scale N2₂ X 23andMe >>> + len @monaid Personal Genome Service Diagnostics Testing Pharmacy / E- Prescribing Telehealth Wellness Reports Medical Records Copyright © 2022 23and Me, Inc. 23andMe 22#23What are Genetic Health Services? Health Predispositions Identifying potential risks then implementing targeted prevention, monitoring, and management Pharmacogenetics Therapeutics that work for you Wellness Targeted to help you feel your best Copyright © 2022 23and Me, Inc. 23andMe 23#24The 23andMe Genetic Health Service is Fully Integrated 1₂ 23andMe Genetic Insights Online doctor visits Mail order pharmacy All connected using a single technology platform ←|→ Long-term Engagement Copyright © 2022 23and Me, Inc. 23andMe 24#25Transforming Therapeutic Development With the 23andMe Database C 4 G C T T#26Limited Use of Genetic Data and Lack of Patient Engagement Constrain Productivity 1. IND Investigational New Drug Application. fdareview.org, "The Drug Development and Approval Process" (2020). 2. Probability of success for a drug to be approved is estimated to be <12%. 3. PhRMA, "Biopharmaceutical Research & Development: The Process Behind New Medicines" (2015). Drug Development is Inefficient 7 years average time-to-IND¹ $2.6B average cost of drug development³ Copyright © 2022 23and Me, Inc. ~90% failure rate2, 3 23andMe 26#27Pharmaceutical Industry 7 years average time-to-IND¹ ~90% failure rate² 23andMe ~4-5 years to IND with current clinical-stage drugs Targets with genetic evidence have historically had a higher success rate³ Publications supporting human genetic evidence for approved drug indications Nelson et al., 2015 (Nature Genetics); King et al., 2019 (PLOS Genetics) ¹ IND = Investigational New Drug Application. fdareview.org, "The Drug Development and Approval Process" (2020). 2 Probability of success for a drug to be approved is estimated to be <12%. PhRMA, "Biopharmaceutical Research & Development: The Process Behind New Medicines" (2015). 3 Nelson et al., 2015 (Nature Genetics), King et al., 2019 (PLOS Genetics) Potential to More Efficiently Develop Novel Therapeutics by "Power, Need, and Speed" 27#28Our Scale Enables Real-Time Genetics Health Research¹ (numbers below represent the number of research participants with the condition indicated) 1,876,573 High cholesterol 1,785,456 Depression 1,113,057 Asthma 634,734 Irritable Bowel 534,696 Arrhythmia 9,047 Systemic Sclerosis 358,275 Type 2 Diabetes 2,355,068 APOE e4 carriers (Alzheimer's risk) 667,019 Eczema 107,126 UC / Crohn's 159,135 Coronary Artery 7,334 Sarcoidosis 37,853 Type 1 Diabetes 85,604 Epilepsy 250,764 Psoriasis 64,800 Barrett's Esophagus 42,836 Pulmonary Embolism 4,528 Idiopathic Pulmonary Fibrosis ¹ As of August 2, 2021. 2 As of September 2021. 3 23andMe COVID-19 manuscript live on MedRXiv September 7, 2020. 1,287,060 COVID-19 study participants COVID-19 Research March 16 April 6 June 8 750K Consumers participated in the COVID-19 study in the first 90 days Sept. 7 (2020) Kicked Off Study Launched Study Preliminary Findings Posted Findings³ Re-contactable Customers Participate in Health Research 28#29Genome-Wide Association Studies (GWAS) GWAS is a statistical analysis of Single Nucleotide Polymorphisms (SNPs), looking To identify differences in frequency between disease cases and controls. SNPs linked with disease will be found at different frequencies in cases versus controls. Association is represented by the level of statistical significance (p-value) of the SNP frequency difference. SNPs can be tested across the genome and mapped to specific regions. Single Nucleotide Polymorphism (SNP) GGCCAGCTGGAGGAGG GGCCAGCTGGAT GAGG -logo(pvalue) 200- 100- 50 20 10 5 2 JEFEEY 1822 6 7 HILA 8 9 Cases 10 11 12 111123 A 14 16 18 20 22 X Copyright © 2022 23and Me, Inc. Controls 23andMe 29#30Example: Number of Osteoarthritis GWAS¹ hits dramatically increase as database grows 2016 2017 2021 -log(pvalue) loga(pvalue) 12 10- Size and Scale Accelerate Target Discovery 60 1 GWAS: Genome-Wide Association Study. 3 6 10 11 12 Chromosome 78930 11 12 Chromosome 7 8 9 10 11 12 Chromosome 14 14 16 18 20 22 X 16 18 20 22 X 16 18 20 22 x Number of independent hits p<5e-8 New programs are identified through GWAS¹ hits, which increase as size of database grows 40,000 35,000 30,000 25,000 20,000 15,000 10,000 5,000 0 2015 2016 2017 2018 Copyright © 2022 23and Me, Inc. 2019 2020 23andMe 30#31Hundreds of Distinct Clinical Phenotypes Across Major and Rare Diseases musculoskeletal cardiovascular eyes Orthopedic Cardiovascular mbi i MYRE Ophthalmology de Phenotype NAFLD (Non-Alcoholic Fatty Liver Disease) neurological gastrointestinal metabolic Neurology G.I. HOW THER Metabolic Disease Cases Controls 48048 2517644 immune autoimmune infection Allergy Autoimmunity Infectious Disease DE BELE Hits New Lost 104 44 2 cancer blood endocrine Copyright 2022 23andMe, Inc. Cancer Hematology imalisattitalli Endocrine obleko dodal... 23andMe 31#32wwwww Genetic Association of the TSLP Signalling Pathway With Asthma PEST Shang Com -FSŁPR- Cell membrane -JAK2 TSLP STAT5 JAK1 I I I IL-7Ra Proinflammatoly signaling I MAT - - VERE TSLP is a well-known cytokine with a role in maintaining immune homeostasis and regulating inflammatory responses at mucosal barriers. The TSLP signaling pathway is an attractive therapeutic - target. e.g. Tezepelumab, a TSLP-blocking monoclonal - antibody for treatment of asthma. Our genetic data shows that multiple genes within the TSLP pathway associate strongly with asthma. Copyright © 2022 23and Me, Inc. 23andMe 32#33We Have Generated a Research and Development Pipeline Covering Multiple Therapeutic Areas Immuno-oncology GSK'608¹ (CD96) EARLY-STAGE THERAPEUTIC AREAS (multiple programs in each area) Immuno-oncology Immunology 23ME'610 (CD200R1) Cardiovascular/ Metabolic Neurology Discovery Preclinical Phase 1 GSK 23andMe 50+ programs² 1. GSK is solely responsible for the development of GSK6097608 (GSK'608) in later-stage clinical trials. Subject to its successful commercialization, 23andMe is eligible to earn tiered worldwide royalties up to the low double digits. 2. The 50+ programs in the combined therapeutic areas include 100% owned and royalty interest targets as well as those in collaborations. The majority of the programs are in collaboration with GSK. Note: As of March 31, 2022 Phase 2 Copyright © 2022 23and Me, Inc. Next Milestone Phase 2 Data Phase 1 Data 23andMe 33#34Breadth of Phenotyping Provides Deeper Genetic Understanding Beyond Single Diseases PheWAS = Phenotype Wide Association Study Every SNP in the genome can be interrogated at >1,000 medically related phenotypes. Besides the role of a gene in a disease of interest, we can use genetics to learn potential indication expansions or possible unwanted toxicities. For TSLP, PheWAS indicates lack of effect in eczema but also highlights potential indication expansion in a rare disease. Asthma TSLP PheWAS crohns- eczema- hashimotos- multiple sclerosis. psoriasis- psoriatic_arthritis - Rare disease A- chinitis. tid. ulcerative colitis - TSLP GWAS signal 1 TSLP GWAS signal 2 TSLP GWAS signal 3 Copyright © 2022 23and Me, Inc. log(OR) 0.2 0.0 -0.2 23andMe 34#35>>> >>> >>> >>> Systematic, Scalable Research Platform Yields Novel Drug Targets Phenotypic Data Genetic Data 10,000s of Genome-Wide Association Study (GWAS) Hits Determine Disease Associated Genes and Directionality Translational Research to Understand Mechanism Identifying Druggable Targets Phenome-Wide Association Studies (PheWAS) Reveal Additional Indications and Potential Safety Concerns Assessment of Unmet Need and Competitive Landscape Best Drug Targets Wet lab validated targets progress through standard stages of research toward the selection of preclinical lead molecules and clinical development 23andMe's database yields thousands of GWAS hits Advanced biology and medicinal chemistry guide design of optimal compounds from initial targets Phenotypic breadth provides unique ability to uncover potential safety issues or possible indication expansions Copyright © 2022 23and Me, Inc. 23and Me 35#3623andMe Immuno-oncology (I/O) Programs#37Large I/O market with $60B in 2021 sales Our I/O Programs Were Identified With ML and AI Applied to Our Proprietary I/O Genetic Signature 2021 sales of leading checkpoint inhibitors KEYTRUDA $17.2B OPDIVO YERVOY $7.5B $2.0B 23andMe's proprietary I/O genetic signature developed with ML which also identifies marketed I/O drugs I/O genetic signature shows opposing effects on autoimmune and cancer phenotypes ansfer or as payung Hypothyroidan Hyperthyidas- vei gh sout equ GHALL HEA M qanos o carcnon karoon tin tal- we cance Autoimmune Cancer We discovered additional targets that have a similar genetic I/O signature CD200R1 (23ME'610) CD96 (GSK'608) + others Copyright © 2022 23and Me, Inc. 23andMe 37#3823ME'610 Targeting CD200R1#39CD200R1 was Identified as a Promising Anti-Cancer Drug Target with 23andMe's Proprietary Immuno-oncology (I/O) Genetic Signature Immune and autoimmune phenotypes Cancer phenotypes Identified novel immuno-oncology signature around CTLA4. tonsillectomy- 110- anli Int alpha or dards juvenile 11d- iqb dry skin frequency- iodine treatment ever- hypothyroidism hyperthyroidism hashimotos- graves- vitiligo- iqb dandruft frequency- celiac HLA all- psoriasis- rheumatoid arthritis- took meds anti tnf alpha- thymid_removed- immunodeficiency- squamous call carcinoma- basal cell carcinoma- actinic keratosis- non melanoma skin cancer- any skin cancer- signed log(p) -100 510 Genetic Variant in CTLA4 linked with multiple phenotypes in the 23andMe database CD200R1 pathway identified as a critical immune checkpoint with our I/O genetic signature CD200R1 Receptor թսոաալ I/O genetic signature shows opposing effects on autoimmune and cancer phenotypes Cancer Cancer Immune CD200 Ligand DOK2 Protein Immune Cancer signed log(p) -10 -5 0 5 10 We discovered that 3 components of the signaling pathway for CD200R1 have a similar genetic signature to other I/O drugs Copyright © 2022 23and Me, Inc. 23and Me 39#40CD200R1 is an Immune Checkpoint CD200R1 is an inhibitory receptor expressed on T-cells and myeloid cells CD200 is the only known ligand for CD200R1 in humans and is highly expressed in certain cancers Binding of CD200 to C200R1 decreases the ability of T-cells to recognize and kill cancer cells Several viruses have co-opted CD200 analogues to suppress and evade the host immune response References: J Virol 2012;86:6246, J Virol 2004;78:7667, J Immunol 2005;175:4441, Structure 2013;21:820, JCI Insight 2018;3:e96836 Tumor cell CD200:CD200R1 Signaling 000 CD200 Reduced antitumor immune response CD200R1 Immune cell OOOPPP DOK2 RasGAP ERKRas Nat Akt Copyright © 2022 23and Me, Inc. 23andMe 40#4123ME-00610 (23ME'610) Binds with High Affinity to CD200R1 and Inhibits Immunosuppressive Signaling 23ME '610 is a fully humanized, effectorless, IgG1 antibody against human CD200R1 23ME '610 binds CD200R1 with high affinity (K₁ < 0.1 nM) 23ME '610 blocks CD200 ligand binding to CD200R1, resulting in inhibition of immunosuppressive signaling The restoration of T-cell activity by 23ME '610 was demonstrated using in vitro models of the tumor microenvironment No adverse effects of blocking CD200R1 have been observed in nonclinical toxicology studies *CD200-expressing cell types include tumor, stroma and endothelial IFN, interferon; IL, interleukin 23ME'610 Activates T-cell Function by Blocking the CD200R1 Checkpoint Tumor cell Tumor cell* CD200 +23ME-00610 CD200R1 Copyright © 2022 23and Me, Inc. T cell ↓IFNY ↓IL-2 Antitumor cytotoxicity Tcell ↑ IFN- ↑ IL-2 Antitumor cytotoxicity 23and Me 41#42CD200R1 is expressed on from The Cancer Genome Atlas (TCGA) tumor-infiltrating lymphocytes (TILs) CD200R1 expression (using RNAseq data from TCGA) is correlated with several immune cell markers: CD4, CD8, CD45 (shown), and CD11b CD200R1 is co-expressed with antigens or markers that are expressed on lymphocytes seen in most cancer types Log(CPM+0.05) of CD45 CD200R1 correlation with CD45 (hematopoietic cells) 2.5 tho 0.86 2.0- 1.5- 1.0- 0.5- KIRC -1.0 -0.5 0.5 1.0 1.5 Log(CPM+0.05) of CD200R1 1. Clear cell renal carcinoma (KIRC) is shown and was chosen because it had high immune infiltration in the TCGA dataset TCGA, The Cancer Genome Atlas; TILs, tumor infiltrating lymphocytes 23and Me 42 Copyright © 2022 23and Me, Inc.#43Inhibition of CD200R1 has the potential to address resistance to anti-PD1 therapies Blocking the CD200R1 pathway enhanced IFNy production from SEB-stimulated PBMCs compared to isotype control and anti-PD1 in the majority of samples tested Interferon-y Fold Change Relative to Control 2 *L Endometrial 1 Ovarian 1 Endometrial 2 Lung Melanoma Pancreatic Endometrial 3 PBMCs from each respective patient were incubated with 100 nM of 23ME-00610, anti-PD-1, or isotype control. Cells were stimulated with SEB. IFNy levels were determined by enzyme-linked immunosorbent assay. Mean biologic triplicates were normalized to isotype control. *P <0.05. 23ME '610 Isotype Control anti-PD1 Prostate Colorectal Copyright © 2022 23and Me, Inc. PBMC, peripheral blood mononuclear cell; PD-1, programmed death-1; SEB, staphylococcal enterotoxin B. 23andMe 43#44Phase 1 Study of 23ME'610 in Patients with Locally Advanced or Metastatic Solid Malignancies 1 Phase 1 Patients with locally advanced, unresectable or metastatic solid tumors that have progressed after or are inappropriate for standard therapy Study Design Y Openlabel Non- Randomized Part A (n = 26) Monotherapy Dose Escalation (IV Infusion Q3W) Accelerated Titration 3+3 Cohorts x RP2D / MTD Multi-center Part B (n = 75) Expansion Cohort Expansion Cohort Expansion Cohort Expansion Cohort Expansion Cohort Primary Objectives Part A: Safety (DLTS, AES) Part B: Efficacy (ORR) Secondary and Exploratory Efficacy (ORR [RECIST and iRECIST]), DOR, PFS, OS) and Safety Pharmacokinetics Pharmacodynamic biomarkers Abbreviations: AEs: Adverse Events; DLT: Dose limiting toxicity; DOR: duration of response; IV: intravenous; ORR: Objective Response Rate; OS: Overall Survival; PFS: Progression Free Survival; Q3W: every three weeks; RECIST: Response Evaluation Criteria in Solid Tumors; RP2D: Recommended Phase 2 Dose Copyright © 2022 23and Me, Inc. 23and Me 44#4523ME'610 Targeting CD200R1: A Genetically-Validated Approach to Anti-Cancer Therapy CD200R1 is an immune checkpoint with a strong I/O signature in three components of the pathway 23ME-00610 is a high-affinity, first-in-class, anti-CD200R1 antibody with immune-activating properties, including: Prevention of CD200-mediated suppression of chronically stimulated T cells Enhancement of cytokine secretion from peripheral blood mononuclear cells (PBMCs) isolated from cancer patients Augmentation of PBMC-mediated tumor cell killing CD200R1 expression was observed on tumor infiltrating lymphocytes from The Cancer Genome Atlas, suggesting that this pathway contributes to an immunosuppressive tumor microenvironment. CD200R1 was also expressed in immune checkpoint inhibitor non-responders, indicating that inhibition of the CD200R1 immune checkpoint has the potential to address resistance to anti-PD-1 and anti-CTLA4 therapies The Phase 1 dose escalation study of 23ME'610 in patients with advanced solid malignancies was initiated in January 2022#46GSK6097608 (GSK'608) Targeting CD96#47The GSK'608 Program is a Prime Example of the Value 23andMe Brings to Drug Discovery and Development Inhibition of CD96 leads to immune activation and tumor growth inhibition in non-clinical models GSK'608 is a high affinity monoclonal antibody against CD96 GSK'608 is currently being evaluated in an ongoing Phase 1 study In January 2022, 23andMe elected to take a royalty option on GSK'608. As a result, GSK is now solely responsible for the development of GSK'608. Copyright © 2022 23and Me, Inc. 23and Me 47#48C G Financials C T#49Investing in Future Growth in a Fiscally Responsible Manner 1 Investing in future growth potential. For those business segments expected to drive future growth, including the new genetic health services and our therapeutics business, we plan to focus on the most strategically and financially valuable options and invest appropriately in each. 2 Employing a conservative approach to planning. Recognizing the current uncertainties in the economy and financial markets, we are prioritizing the minimization of Adjusted EBITDA deficit rather than maximizing top-line growth in our Consumer business (PGS and telehealth). 3 Solid cash position. Cash of $479 million¹ supports 23andMe's plans for significant investment in Therapeutics portfolio and strategic initiatives. ¹As of June 30, 2022. Copyright © 2022 23and Me, Inc. 23andMe 49#50(in $M, except percentages) Consumer Services Research Services Therapeutics Total Revenue Revenue Composition Amount $56 8 $65 Three Months Ended June 30, FY2023 Percentage of Revenue 87% 13% 100% Amount $48 11 $59 FY2022 Percentage of Revenue 81% 19% 100% Year Ended March 31, Amount $222 50 $272 Copyright © 2022 23and Me, Inc. FY2022 Percentage of Revenue 82% 18% 100% 23andMe 50#51Consumer Services Revenue Seasonality by Quarter FY 2019 FY 2020 FY 2021 FY 2022 Note: Fiscal year ends March 31. Q1 28% 24% 18% 22% Q2 19% 24% 21% 20% Q3 18% 21% 22% 21% Q4 35% 31% 39% 38% Copyright © 2022 23and Me, Inc. Full Year 100% 100% 100% 100% 23andMe 51#52(in $M, except percentages) Therapeutics Research and Development Expense Consumer and Research Services Total R&D Expense Amount $24 28 $52 Three Months Ended June 30, FY2023 Percentage of total R&D expense 46% 54% Amount $21 23 $44 FY2022 Percentage of total R&D expense 47% 53% Copyright © 2022 23and Me, Inc. YoY % Change 15% 20% 23andMe 52#53Sales and Marketing Expense Composition (in $M) Advertising and Brand Personnel-related expenses Outside Services, equipment and supplies Depreciation and Amortization Facilities and other OH Alloc Total S&M Expense Note: Balances may not add up due to rounding Three Months Ended June 30, FY2023 Amount $21 6 1 3 2 $33 FY2022 Amount $9 3 1 2 $15 Copyright © 2022 23and Me, Inc. 23andMe 53#54Segment Information and Reconciliation of Non-GAAP Financial Measures Note: Fiscal year ends March 31. (unaudited) (in $K) Segment Revenue Consumer & Research Services Therapeutics Total Revenue Segment Adjusted EBITDA Consumer & Research Services Therapeutics Unallocated Corporate Total Adjusted EBITDA Reconciliation of Net Loss to Adjusted EBITDA Net Loss Adjustments: Interest (income), net Other (income) expense, net Change in fair value of warrant liabilities Income tax benefit Depreciation and amortization Amortization of acquired intangible assets Stock-based compensation expense Total Adjusted EBITDA Three Months Ended June 30, FY2023 Amount $64,513 $64,513 ($16,997) (18,465) (14,253) ($49,715) ($89,532) (245) 435 (254) 5,104 4,315 30,462 ($49,715) FY2022 Amount $59,239 $59,239 ($505) (18,303) (8,467) ($27,275) ($42,026) (44) (14) 534 4,638 9,637 ($27,275)#55How 23andMe Helps People Access, Understand, and Benefit from the Human Genome Jess 13.1M Genotyped Customers¹ 23andMe Welcome to you Personal Genome Service + 80+ PGS Reports² fee lem 23andMe pie Healthcare services available in all 50 states Genetic Health Services4 1. As of June 30, 2022. 2. Includes Health Predisposition, Wellness, Carrier Status and Pharmacogenetic Reports, including those in 23andMe+ subscription service. 3. As of March 31, 2022. 4. Future services currently in development. + 50+ Programs³ Therapeutics Copyright © 2022 23and Me, Inc. 23andMe 55#56C G Appendix C T#57The Vast Majority of GWAS Discoveries Can be Made Without Large-scale Sequencing Nearby genetic variants are correlated with each other. Knowing the variant in one position allows nearby variants to be inferred. E.g. Fill in the blanks: The q***k brown f*x jumps ov*r the **zy dog. The same principle applies in genetics. The process of filling in the gaps is known as 'genotype imputation'. ● We type ~650,000 SNPs using our genotyping array, which allows accurate imputation for >35m SNPs in the genome. Genotype imputation is much more cost effective than large- scale sequencing. • Whole-genome sequencing -$1000/sample. Exome sequencing ~$400 / sample. Imputation < $0.01/ sample We do deploy sequencing in situations where there is a clear benefit over and above imputation (e.g. rare disease). Genotyped Samples 1 1 2 2 0 1 2 2 1 2 1 1 2 2 2 2 121 111122 022 20: 2 2 1 1 1 0 1 0 -logp-value 20 15 in O 20- 15 2 176.3 0 1 2 0 2 2 Un 1 0 88% 176.4 Reference Genomes 1100 176.5 611 2011077 rs1906265 Imputation Process 1212121201127120 12121?1701077170 1717171711177170 6090 %00 Doo 0101 110 01 170?0?0?1112?170 017070711177170 176.6 176.7 Position on chr5 (Mb) 176.8 Copyright © 2022 23and Me, Inc. 176.9 2 Imputed Samples 1 1 102 2001 012 201 1 20110120 2 2 2 2121 1101 101 22 022 2021 1101 2 2 1 1 100 0 177 2 2 0 23andMe 2 0 0 2 2 1 2 1 0 Before imputation After imputation 57#581 23andMe's Value Proposition Disrupting the Healthcare experience. 23andMe is building a personalized health and wellness experience that caters uniquely to the individual by harnessing the power of their DNA. Integrating Lemonaid Health's online digital health platform to deliver personalized, prevention-oriented, genetically- based healthcare at scale The world's premier re-contactable phenotype-linked genetic database. A vast (>13M genotyped 2 customers) proprietary dataset rich with both genotypic and phenotypic (health) information allows insights that unlock revenue streams across digital health, therapeutics, and much more Continuously increasing quantity and quality of phenotypic data. Impressive customer participation 3 provides >4 billion phenotypic data points for unprecedented statistical power to discover new insights into health and potential therapies. Over 50 identified therapeutic programs validates the approach of developing novel therapeutics 4 using genetic data. One program in clinical development with GSK, one wholly owned program started clinical trials in January 2022. Difficult to replicate platform for value creation. The FDA-approved consumer platform, the 5 therapeutics efforts, and the rich database combine to create multiple opportunities for substantial value creation 6 Solid cash position. Solid balance sheet supports 23andMe's plans for significant investment in therapeutics portfolio and strategic initiatives Copyright © 2022 23and Me, Inc. 23and Me 58